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ABSTRACT  
The Papanicolaou (Pap) smear was introduced in the 1960s as the official cervical cancer 
screening method in Latin America.  However, the reduction of cervical cancer incidence and 
mortality in this region has not been as successful as that achieved in developed countries, as 
cervical cancer remains the first or second leading cause of death due to cancer for Latin 
American women (Yunes-Díaz, Ruiz, & Lazcano-Ponce, 2015). Multiple studies have 
established that the Pap smear has a low sensitivity (40% to 80%) and a high false negative rate 
(25% to 50%) (Flores, et al., 2010; Murillo, Almonte, Pereira, Ferrer, Gamboa, Jerónimo & 
Lazcano-Ponce, 2008; Murillo, Herrero, Sierra & Forman, 2016). New emerging technologies, 
such as HPV testing, have demonstrated a greater sensitivity, and can identify high-grade cervical 
cancer earlier than Pap smears.   
The purpose of this literature review was to analyze and compare the cost-effectiveness of 
Pap smear alone versus Pap smear combined with HPV testing as part of a standardized cervical 
cancer screening program in Latin America. A total of 30 articles and cost-effectiveness analyses 
were included in this literature review.   
The cost of Pap smear alone at first sight seems to be lower than that of HPV testing, but 
when the cost of false negatives are taken into account, the total costs associated with the Pap 
smear exceed those of other tests with fewer false negatives.  The use of the Pap smear and HPV 
testing combination ends up being less expensive for its potential to identify 98% of cervical 
cancer cases, which represents 64% more cases than the Pap test alone (Flores, et al., 2010; 
Goldie & Gaffikin, 2005; Granados-García, Flores, Pérez,  Rudolph, Lazcano-Ponce & 
Salmerón,  2014; Mandelblatt, Lawrence, & Gaffikin, 2002). Most of the reviewed cost-effective 
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analyses indicate that including HPV testing into an already existing cervical cancer screening 
program could be a highly cost-effective screening alternative for most of the national health 
delivery institutions. These results may help policy-makers implement HPV testing as part of the 
cervical cancer screening programs in Latin America (Flores, et al., 2010).  
 
KEYWORDS:  Cervical cancer, Papanicolaou (Pap) smear, Human Papillomavirus (HPV), HPV 
testing, Cost-effective analysis, Latin America.  
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INTRODUCTION  
In 2012 alone, there were almost 530,000 new cases of invasive cervical cancer in the 
world, 15% of which occurred in Latin America (Ferlay, Soerjomataram, Ervik, Dikshit, Eser, 
Mathers, … & Bray, 2012). Latin America, with nearly 600 million inhabitants, continues to bear 
an excessive burden of cervical cancer, with the second highest incidence and mortality rates in 
the world. The age-standardized incidence rate has been estimated to be almost 30 per 100,000, 
and mortality rate at 14 per 100,000 (Ferlay, et al. 2012). Papanicolaou (Pap) smear was 
introduced in Latin America in the 1960s as the official cervical cancer screening method; 
however, the effort to reduce of cervical cancer incidence and mortality has not been as 
successful as that achieved in developed countries. According to population indicators, cervical 
cancer mortality rates remained almost unchanged between 1975 and 2000 in Latin America 
(Murillo, et al., 2008). There has been a slight decrease over time only in a few countries such as 
Mexico, Costa Rica and Chile (Murillo, et al., 2008). In the 1990’s, the identification of the 
human papillomavirus (HPV) as the etiologic agent of cervical cancer, led to two major 
advances. The first is the development of a preventive vaccine, and the second is the 
incorporation of HPV testing into existing screening programs. It has been demonstrated that 
HPV testing has a greater sensitivity that can identify high-grade cervical cancer earlier than Pap 
smears. These results suggest that HPV testing has the potential to reduce the incidence of 
cervical cancer and, due to its sensitivity, it may permit increased intervals for screening (Lowy, 
et al., 2008). HPV testing could improve secondary prevention screening programs and it 
represents an opportunity for a more efficient reduction in the incidence and mortality rates of 
cervical cancer. Undertaking HPV testing along with Pap smear has the potential as a more cost-
effective strategy for developing countries if it can prevent treatment, hospitalizations, and loss of 
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productivity due to invasive cervical cancer deaths (Lowy, et al., 2008). Cervical cancer is the 
first or second most frequent cancer among women in the majority of the countries in Latin 
America; in 2012, there were 64,000 new cases of invasive cervical cancer and more than 26,000 
deaths. If screening interventions are not improved, there will be a doubling in the number of 
cases in the next 15 years (Murillo, et al., 2016).  
This literature review compared the effect of single Papanicolaou (Pap) smear practiced 
as a cervical cancer screening method versus Papanicolaou (Pap) smear in combination with HPV 
testing in Latin America, to determine if the combination of screening methods is economically 
feasible and more efficient in reducing cervical cancer incidence, and therefore its mortality. The 
focus of studies examined for this undertaking included current cervical cancer screening 
methods in women between 30 and 65 years of age in Latin America, and related cost-
effectiveness analysis.  The research questions explored included: (1) Is the combination of Pap 
smear and HPV testing more effective in detecting cervical cancer than single Pap smear? and (2) 
Is the combination of Pap smear and HPV testing more cost-effective than single Pap smear?  
CURRENT LANDSCAPE  
Cervical Cancer Generalities 
According to the National Institute of Health (NIH), cancer refers to a group of related 
diseases caused by changes in the genes that determine the way cells function, grow and divide 
(National Institute of Health [NIH], 2015).  The nature of these changes led to a faster and 
uncontrolled division and growth of abnormal cells, with the potential to spread to other organs. 
In the specific case of cervical cancer, such changes occur in the cells located in the cervix of the 
uterus.  Two important characteristics of cervical cancer are its preventability and its viral 
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etiology. Research has concluded that virtually all cases of cervical cancer are attributable to 
persistent infection by the human papillomavirus (HPV). HPV is a sexually-transmitted virus 
with a high infection prevalence; it is usually unknowingly transmitted due to its asymptomatic 
nature and long incubation period. It has been estimated that more than 50% of sexually active 
women acquire HPV, making it the most prevalent sexually transmitted disease (Lowy, 2008). 
Multiple types of HPV have been identified, and they are classified as low-risk and high- risk 
types according to its association with genital warts and cervical cancer, respectively. HPV type 
16 (HPV-16) and HPV-18 are classified as high-risk types due to a strong relation to the vast 
majority of cervical cancer cases. These HPV types are also associated to other types of cancer, 
including vulvar, vaginal, anal, penile, and oropharyngeal cancers (Tovar, Bazaldua & Vargas, 
2008).  
Such HPV types associated with cervical cancer are the same around the world. HPV-16 
accounts for almost 50% of all cervical cancers, and is the most frequently identified type in all 
regions. The second most common type is HPV-18, and it is typically found in 15% to 20% of 
squamous cell cancers and in greater proportions of adenocarcinomas (both are high-grade types 
of cervical cancers). HPV types 6 and 11 are the most common low-risk types found, and they are 
associated with genital warts. (Lowy, et al., 2008) 
Historical Background 
The Pap smear was introduced for cervical cancer detection in the 1940’s with a rapid 
widespread implementation in the 1950s.  In the 1990’s, human papilloma viruses were linked to 
the etiology of this cancer and a better understanding of its pathogenesis has been gained. The 
widespread use of the Pap smear and HPV’s association to cervical cancer, have progressively 
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contributed to the greater emphasis on the prevention of invasive cancer, and significant 
reductions in the incidence of cervical cancer have been achieved. (Granados-Garcia, et al., 
2014). However, the incidence of this cancer remains high in many low and middle-income 
countries, due to lack of resources for widespread screening programs as practiced in nations with 
greater resources such as the United States.  
Cervical Cancer Statistics 
Cervical cancer is the fourth most frequent cancer in women worldwide, and the seventh 
overall, with nearly 530,000 new cases just in 2012, representing 7.9% of all female cancers 
(Ferlay, et al., 2012). The highest incidence is in Africa, Latin America and the Caribbean; and 
the lowest incidence is found in the United States, Canada, and Oceania. In 2015, almost 270,000 
women died of cervical cancer in the world, 90% of which occurred in low- and middle-income 
countries (World Health Organization [WHO], 2018), where it accounts for almost 12% of all 
female cancers. (Ferlay, et al., 2012) 
Poverty is the strongest determinant of cervical cancer incidence and mortality, with 
developing countries showing the highest incidence and mortality rates, 15.7 versus 3.3 per 
100,000 population in the less and the most developed countries in the world, respectively 
(Murillo, et al., 2016). The human development index (HDI), which refers to an index of progress 
measuring life expectancy, education level and income (United Nations [UN], 2017), has shown 
an inverse association and poverty rates a direct association with incidence and mortality, 
explaining about 52% of cervical cancer variability globally. In Latin America, countries with the 
highest mortality rates are those with the lowest per capita gross domestic product (GDP) 
(Murillo, et al, 2016). 
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According to a retrospective study by Murillo et al., identified cervical cancer as the 
leading female cancer diagnosis in El Salvador and Bolivia and the second leading female cancer 
in Mexico, Argentina, Colombia, Ecuador, French Guyana, and Peru (Murillo, et al., 2016).  
They found during the last 20 years, that the highest incidence was 30 and 29 per 100,000 
population in French Guyana and El Salvador respectively, while Costa Rica, Chile, Mexico, and 
Cuba showed rates under 15 per 100,000 population. The highest mortality rates were 17 and 15 
per 100,000 population observed in Belize and Paraguay respectively, and in descending order 
between 10 and 15 per 100,000 in the following countries: El Salvador, Nicaragua, Venezuela, 
Suriname, and Ecuador. The lowest mortality rates, ranging from 6.0 to 7.3, were observed in 
Chile, Uruguay, Brazil and Costa Rica (Murillo, et al., 2016). 
Current Cervical Cancer Screening Trends 
The Pap smear is currently the primary cervical cancer screening method used worldwide, 
and in some countries, it has significantly reduced the disease burden from cervical cancer 
(Almonte, Murillo, Sánchez, Jerónimo, Salmerón, Ferreccio, … & Herrero, 2010). Until the early 
2000’s, strategies to prevent cervical cancer were based on abstinence, condom usage, and timely 
detection with the Pap smear. It has been demonstrated that a well-organized cervical cancer 
screening program has the potential to reduce cervical cancer by 60% to 90% in the three years 
after screening (Almonte, et al., 2010). However, research has found the existence of multiple 
factors contributing to the ineffectiveness of a cervical cancer screening program.  One of the 
most important factors is the high false negative rates of the Pap test that can delay diagnosis or 
lead to a misdiagnosis. Some other factors include poor quality of care, lack of access to 
screening services, and inadequate follow-up of results (Flores, et al., 2010). Multiple studies 
have established that the Pap smear has a low sensitivity, ranging from 40% to 80% for high-
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grade cervical cancer; the consequence of this low sensitivity is a false negative rate of 25% to 
50% (Flores, et al., 2010; Murillo, et al., 2008; Murillo, et al., 2016).  
The less-than-optimal performance of the Pap smear has led to the creation of alternative 
screening technologies (Tovar, et al, 2008). HPV tests were adopted to improve secondary 
prevention, as well as contributed to the development of vaccines as the primary prevention of 
infection from the four most common HPV types (HPV types 6, 11, 16, and 18) (Tovar, et al., 
2008). This paper will focus on the implementation, cost-effectiveness, and outcomes related to 
the Pap smear, the HPV testing, and the combination of both in Latin America.  
The majority of Latin American countries have conventional cervical cancer prevention 
programs which rely mainly on repeated rounds of Pap smears, occurring every one to three 
years. Despite the existence of a national cervical cancer screening program in most of the Latin 
American countries since the early 1979’s, and despite technological and scientific advances, 
cervical cancer remains the first or second leading cause of death due to cancer for Latin 
American women (Yunes-Diaz, Ruiz & Lazcano-Ponce, 2015). Multiple studies evaluating the 
effect of national cervical cancer screening programs in Latin America have found a modest 
decrease in mortality due to this cancer in the last two decades (Rodríguez & Salmerón, 2017; 
Vanslyke, Baum, & Plaza, 2008; Villa, 2012). Even when one of the leading determinants of this 
decrease is an increase in early detection through use of the Pap smear, these studies found a 
constant low rate of high-grade cervical cancer detection due to poor quality in the Pap smear 
collection process and the technical cytological diagnosis (Flores, et al., 2010). In most of the 
Latin American countries, this situation was mainly attributed to poor quality sample collection 
and cytological diagnosis (Murillo, et al., 2008). Just a few Latin American countries have 
included testing for HPV directly by molecular assays along with the Pap smear (Appendix C), to 
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provide better risk prediction and the possibility of fewer cycles of screening (Luciani, Cabanes, 
Prieto-Lara & Gawryszewski, 2013). Multiple studies have found that when HPV testing is added 
to the Pap smear, the sensitivity of the combination is improved compared to Pap smear alone 
and to HPV testing alone. In all of the studies the sensitivity obtained by using the combination 
of methods exceeded 92%, and in the majority, sensitivity exceeded 95% (Jr, Schiffman, & 
Solomon, 2004). Another benefit of using HPV testing along with the Pap smear is that it 
identifies both, women with current cervical disease, as well as those at risk of developing 
cervical disease in the future; whereas the Pap smear alone only identifies ongoing cervical 
disease (Jr, Schiffman, et al , 2004).  
METHODOLOGY  
A search in PubMed®, Scopus®, Global Health® and Cochrane® databases was carried 
out. National health surveys and databases from Latin American countries, as well as WHO and 
CDC reports on cervical cancer were also reviewed to verify cervical cancer incidence and 
mortality rates in these countries.  
The keywords used for the search were: 
Cervical OR HPV OR cervix OR papillomavirus 
AND  
Cancer* OR neoplas* 
AND 
Prevention OR control OR screening OR pap smear OR test* OR Papanicolaou OR diagnosis OR 
detection OR cytology OR screen 
AND 
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Latin America OR south America OR Central America OR Mexico OR Argentina OR Venezuela 
OR Peru OR Chile OR Colombia OR United States  
AND 
Mortality OR outcome* 
AND 
Cost-effective OR cost-effectiveness OR "cost effective" OR "cost effectiveness" OR economic 
challenges OR efficacy OR success OR sustainab* OR programs OR shortcomings OR strategy 
OR resources OR barriers OR facilitators 
The search resulted in a total of 1,168 articles, of which 583 were screened, and 276 were 
assessed for eligibility. 
A total of 246 articles of studies: 1) with results from specific interventions such as HPV 
vaccination and visual inspection with acetic acid (VIA) as a cervical cancer screening method, 
2) with a primary focus on evaluating cervical cancer screening coverage, treatment and follow-
up of positive screening results, as well as 3) conducted with data from other countries rather than 
Latin American countries, were excluded (Appendix A).  
A total of 30 articles of studies including cervical cancer screening programs for women 
between 30 and 65 years of age in Latin America were included, as well as those studies 
evaluating the effects and cost-effectiveness of single Pap smear, single HPV testing, and its 
combination. All the articles and the cost-effectiveness analyses consulted for this literature 
review were conducted with data collected from public healthcare national institutions (Appendix 
B). 
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The results and conclusions expressed in this literature review are based on the data 
collected from articles publishing observational, retrospective, randomized controlled trial, and 
cross-sectional studies; as well as cost-effectiveness analyses examining the specific costs and 
health outcomes associated with different cervical cancer screening methods, such as: Pap smear 
alone; HPV testing alone; and Pap smear in combination with HPV testing.  
RESULTS  
There is a wide variation regarding cervical cancer screening programs among countries 
in Latin America.  The introduction of these programs spans over more than three decades in 
some cases (Murillo, et al., 2008). Recommendations regarding the age for starting cervical 
cancer screening varies from 15 to 35 years and for screening cessation ranges from 49 to 70 
years (Muñoz & Herrero, 2011).  Most of the screening programs in Latin America are based on 
one Pap smear every three years after two negative annual Pap smears; however, some countries 
continue to perform Pap smears as often as once a year with inadequate follow-up and without an 
established correlation between screening intervals and screening coverage (Murillo, et al., 2008) 
After reviewing the available literature, it was found that Pap smear-based national 
screening programs have been successfully implemented in some countries in Latin America. An 
example is Chile, where the Pap smear was implemented in the 1960s, with an official launch of 
a very well organized national screening program in 1994.  It is mandated that women ages 25 to 
64 years get screened with conventional Pap smear every three years. Chile has computerized this 
screening program since the late 1990s, which has allowed the identification, tracking, and 
follow-up of patients, a commendable effort. In 2005, cervical cancer screening was included free 
of charge for every woman 25 to 64 years of age to ensure an adequate evaluation and treatment 
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of every identified cervical precancerous lesions and other identified cancers. This policy has 
contributed to the increase of screening coverage and program performance (Villa, 2012; 
Ministerio de Salud de Chile, 2004).  
Another successful example is Brazil, where the screening program was first piloted in 
1968, and is the first Latin American screening program in existence for more than 30 years. The 
national screening program was launched in 1998 (Muñoz & Herrero, 2011). The Brazilian 
national program includes Pap smear detection, diagnosis and treatment free-of-charge for 
women ages 25 to 59 years every three years after two consecutive annual negative smears 
(Rodriguez & Salmerón, 2017). However, this is not the case for the majority of the countries in 
Latin America, where the typical situation is poor screening coverage and lack of proper follow-
up.  
Effectiveness of Pap smear and HPV testing  
Research has identified the existence of multiple factors affecting the effectiveness of a 
cervical cancer screening program.  One of the most important factors is the high false negative 
rates of the Pap smear test that can delay a diagnosis of cancer or lead to a misdiagnosis. Some 
other factors include poor sampling and processing quality (Flores, et al., 2010). Multiple studies 
have also established that the Pap smear has a low sensitivity, ranging from 40% to 80% for high-
grade cervical cancer.  The consequence of this low sensitivity is a false negative rate of 25% to 
50% (Flores, et al., 2010; Murillo, et al., 2008; Murillo, et al., 2016). In one of the studies, 20 
laboratories in Mexico were evaluated by distributing a panel of 220 cervical Pap smear 
specimens that were processed and then compared with the reference standard. Almost 70%  of 
the laboratories in the study had more than 25%t false negative results, and four laboratories had 
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more than 45% false negative results, including a total of 31 false negative diagnoses of high-
grade cancer (Lazcano-Ponce, et al, 2008; Lazcano-Ponce, et al, 2009). It is necessary to improve 
the poor results currently obtained through Pap smear based screening programs in the region, by 
redirecting efforts and resources (Murillo, et al., 2008).   
Evidence has demonstrated that new emerging technologies should be carefully 
considered in order to improve cervical cancer screening programs in Latin American countries 
(Jeronimo & Holme, 2016). It has been demonstrated that HPV testing has a greater sensitivity 
and can identify high-grade cervical cancer earlier than Pap smears. Therefore, HPV testing has 
the potential to reduce the incidence of cervical cancer, and due to its sensitivity, it may permit 
increased intervals for screening. (Lowy, et al., 2008). HPV testing could improve secondary 
prevention screening programs; and it represents an opportunity for a more efficient reduction in 
the incidence and mortality rates of cervical cancer. HPV testing along with the Pap smear have 
the possibility of being a more cost-effective strategy to the developing world, if it can prevent 
treatment, hospitalizations, and loss of productivity due to invasive cervical cancer deaths (Lowy, 
et al., 2008). 
HPV testing has not only proven to have higher sensitivity than Pap smear, but has also 
demonstrated an additional advantage due to  testing automatization and lower human 
dependency, reducing quality control problems (Andrés-Gamboa & Chicaíza, 2008).  
Cost- effectiveness of the combination of Pap smear and HPV testing  
HPV testing has a very high predictive value that permits longer screening intervals that 
could improve follow-up and reduce costs (Beal, Salmerón, & Flores, 2014). Screening with 
HPV testing followed by Pap smear of positive results could be a more cost-effective option than 
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frequent use of the Pap smear (Murillo, et al., 2008). The average cost found in the literature to 
perform the HPV testing was $20 USD per patient; the Pap smear cost was $13.20 USD; and the 
HPV testing in combination with the Pap smear cost was $26.18 USD.  
A study by Granados-Garcia and colleagues found that the cost to perform three million 
Pap smear tests was nearly 40 million USD, representing almost 30% of the total program cost. 
False negatives accounted for nearly 45% of the total program costs.  The low sensitivity of the 
Pap smear test generating high rates of false negatives, results in high costs from the treatment of 
undetected cervical cancer cases (Granados-García, et al., 2014). All the cost-benefit analyses 
from Latin American countries have consistently shown the need for highly sensitive tests for 
screening strategies to be effective (Andrés-Gamboa, et al, 2008). The results of most of the cost-
effectiveness analyses indicate that screening women between the ages of 30 to 70 for cervical 
cancer using the combination of HPV testing and the Pap smear is always more cost-effective 
than using the Pap test alone (Flores, et al., 2010; Goldie, et al, 2005; Granados-García, et al., 
2014; Mandelblatt, et al, 2002). 
At first glance, it seems like Pap smear alone is the most reasonable and feasible option; 
but when the cost of false negatives are taken into account, the total costs associated with the Pap 
smear exceed those of tests with fewer false negatives.  Further, the use of the Pap smear and 
HPV testing combination ends up being less expensive for its potential to identify 98% of 
cervical cancer cases, which represents 64% more cases than the Pap test alone. (Flores, et al., 
2010; Goldie & Gaffikin, 2005; Granados-García, et al., 2014; Mandelblatt, Lawrence, & 
Gaffikin, 2002). 
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LIMITATIONS 
This literature review did not take into account studies analyzing the sensitivity, 
specificity, and cost-effectiveness of cheaper available cervical cancer screening methods such as 
the visual inspection with acetic acid (VIA) which may be a more appropriate and feasible 
screening option for rural and low income settings. Additionally, this literature review did not 
consider HPV vaccination, which is already included in many Latin American countries as part of 
their strategies to address cervical cancer; the introduction of this vaccine may have influenced 
cervical cancer incidence rates in some of these countries. Further analyses regarding the effect of 
the inclusion of HPV vaccination into the national cervical cancer screening program of some 
countries in Latin America should be considered, as well as other potential combination of 
screening methods such as VIA + Pap smear, or VIA + HPV testing.  
CONCLUSION  
Cervical cancer remains the first and second most common cause of death from cancer in 
Latin American women that is primarily due to lack of the resources for widespread high-quality 
screening (Bosh, Robles, Díaz, Arbyn, Baussano, Clavel, … & Cuzick, 2016). Multiple studies 
have concluded that  challenges remain from the lack of inclusion and coverage of women over 
30 years of age, living in rural areas, and of low socio economic status; that is problematic as 
these women are identified as a high-risk population (Luciani, Cabanes, Prieto-Lara, & 
Gawryszewski, 2013). These quality and economic challenges could be addressed through the 
improvement of current Pap smear-based programs by the inclusion of high-quality screening. 
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When deciding what cervical cancer screening method is the most appropriate to 
implement in Latin American countries, multiple factors should be considered. Evidence 
indicates that the Pap smear test alone is less accurate and less effective and is a more expensive 
screening option. The cost of the Pap smear test itself is not high, but the cost of the false 
negatives is significant (Flores, et al., 2010). Public health screening programs are spending more 
money on Pap smears testing given its related high false negative rates than it would spend by 
including HPV testing, and so the implementation of HPV testing should be carefully considered 
(Goldie, et al, 2005). The use of HPV testing to complement Pap smear-based screening 
demonstrated a higher sensitivity and accuracy for the early detection of cancer and precancerous 
lesions.  This indicates that HPV testing is able to detect true cancer precursors. Additionally, the 
choice of HPV testing would allow longer intervals between screenings, versus repeated cytology 
at shorter intervals, which is beneficial for efficiency and cost (Lowy, et al. 2008). The results 
from the cost-effective analyses indicate that HPV testing is significantly more effective at 
detecting cervical cancer cases and is less expensive than the Pap smear test, when one considers 
the average costs incurred by the tests and the documented high false negatives (Flores, et al., 
2010).  
It seems an appropriate course of action to make use of the existing clinical resources and 
infrastructure to improve both the quality and effectiveness of the current cervical cancer 
screening programs in Latin America (Jr, Schiffman, et al, 2004). Implementing the use of the 
HPV testing and the Pap smear combination, would greatly improve the case detection 
capabilities of the cervical cancer screening programs in Latin America, with a little or no 
additional cost (Lazcano-Ponce, et al, 2009). Most of the reviewed cost-effective analyses 
indicate that including HPV testing into already existing cervical cancer screening programs, 
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would be a highly cost-effective screening alternative for most of the national health delivery 
institutions. These results may help policy-makers implement HPV testing as part of the cervical 
cancer screening programs in Latin America (Flores, et al., 2010). 
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APPENDIX 
Appendix A. Flow diagram of literature search and study selection process 
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countries (not in Latin America) 
- Studies evaluating HPV 
vaccination effects 
-Studies analyzing VIA 
effectiveness 
- Studies conducted before the 
year 2000 
- Studies evaluating population’s 
knowledge about cervical cancer 
screening methods  
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Appendix B. Findings from Review of Included Studies of the Sensitivity, Specificity, and 
Cost-Effectiveness of Different Cervical Cancer Screening Methods in Latin America 
Study Population  
Method/ 
Study Design 
Comparison  Setting 
Outcome 
Measures 
Results 
Almonte 
et al., 
2010 
50,159 
women 20-70 
years of age in 
a 12-month 
period 
Cervical cancer 
screening: 
Combination of 
Pap smear and 
HPV testing 
Pap smear results 
versus HPV testing 
results 
Rural areas 
in Mexico 
Number of 
positive HPV 
tests, and 
number of 
abnormal Pap 
smears 
 
1. Positivity: 
-Pap smear: 2.2% (95%CI: 2.0-
2.3) 
-HPV testing: 8.6% (95%CI: 8.3-
8.9) 
 
2. Sensibility: 
-Pap smear: 40% (95%CI: 38.5-
41.4) 
-HPV testing: 93.3%  (95%CI: 
92.5-94.0) 
 
3. Specificity:  
-Pap smear: 97% (95%CI: 96.5-
97.5) 
-HPV testing: 89. 2% (95%CI: 
88.3-90.1) 
Andrés-
Gamboa 
et al, 
2008 
The age range 
for Pap smear-
based 
screening is 21 
to 69 years 
and for HPV 
testing, 30 to 
69 years 
Markov model 
to simulate the 
natural history 
of cervical 
neoplasias 
(DATA 4.0 ©). 
No screening, 
Pap smear, and 
HPV testing 
were compared 
The model predictions 
were compared with 
published data on 
incidence of HPV, 
cervical intraepithelial 
lesions, and cancer 
among Colombian 
women, as well as with 
data on mortality from 
cervical cancer and 
previously published 
models (cohort, clinical 
trials, population 
cancer registries, etc.) 
Colombia Reduction of 
cervical 
cancer 
mortality, 
years of life 
saved (YLS), 
and lifetime 
costs  
HPV testing every five years was 
the most cost-effective method, 
with an Incremental Cost-
Effectiveness Ratio (ICER) of 
USD$44/YLS (if the cost per test 
is under USD$31) based on 
Colombian per capita GDP of 
US$3.200, with 69% expected 
mortality reduction.  
Beal, C.M. 
et a, 2014 
This analysis 
assumes a 
population of 
6 967 594, 
which 
corresponds 
to 40% of the 
total 
population of 
Mexican 
women 
between the 
ages of 35 and 
64 years old 
covered by 
The Mexican 
Institute of 
Social Security 
or the 
Ministry of 
Health 
A cost analysis 
of the 
implementation 
of different 
cervical cancer 
screening 
methods.  
Comparison of the 
implementation of 
different cervical 
cancer screening 
methods: Pap smear 
alone, HPV testing 
alone, and Pap smear 
combined with HPV 
testing.  
Mexican 
Institute of 
Social 
Security 
(the main 
Public 
Hospital in 
Mexico) 
The main 
outcome was 
the total cost 
of each 
alternative, 
which was 
defined as 
the screening 
and 
diagnostic 
costs plus the 
cost to treat 
the cervical 
cases 
detected with 
each 
screening 
strategy 
1. Final cost: 
-Pap smear: USD$168.7 million 
-HPV testing: USD$133.8 million 
-Combined: USD$137.3 million 
 
2. Missed cases: 
-Pap smear: 9,079 
-HPV testing: 717 
-Combined: 630 
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Study Population  
Method/ 
Study Design 
Comparison  Setting 
Outcome 
Measures 
Results 
Flores, 
Yvonne N. 
et al, 
2010 
A total of 
7,868 women 
ages 25 to 65, 
between May 
and October 
1999 
A cost-
effectiveness 
analysis 
examining the 
specific costs 
and health 
outcomes 
associated with 
different 
cervical cancer 
screening 
methods 
Comparison of the 
implementation of 
different cervical 
cancer screening 
methods: Pap smear 
alone, HPV testing 
alone, and Pap smear 
combined with HPV 
testing. 
Mexican 
Institute of 
Social 
Security 
(the main 
Public 
Hospital in 
Mexico) 
Cost of 
different 
cervical 
cancer 
screening 
methods. The 
health 
outcome was 
defined as 
the number 
of high-grade 
cervical 
intraepithelial 
neoplasia or 
cervical 
cancer cases 
detected. 
Total cost per test:  
- Pap smear: USD$72.19 
- HPV testing: USD$52.46 
- Combined: USD$54.92 
 
Sensitivity:  
- Pap smear: 59.4% 
- HPV testing: 93.1%  
- Combined: 98% 
 
Specificity:  
- Pap smear: 98.3% 
- HPV testing: 91.8% 
- Combined: 91.1% 
 
 
Goldie, 
Sue J. et 
al, 2005 
Using primary 
data from 
studies in 
countries with 
diverse 
epidemiologic 
profiles and 
resources the 
authors 
assessed the 
cost-
effectiveness 
of alternative 
strategies to 
reduce the 
rate of death 
from cervical 
cancer 
Computer-
based models 
were used to 
assess the cost-
effectiveness of 
a variety of 
cervical-cancer 
screening 
strategies 
Primary data were 
combined with data 
from the literature to 
estimate age-specific 
incidence and mortality 
rates for cancer and 
the effectiveness of 
screening for and 
treatment of 
precancerous lesions. 
Peru Lifetime 
cervical 
cancer risk 
reduction and 
cost of pap 
smear and 
HPV testing 
Lifetime cervical cancer risk 
reduction: 
-Pap smear: 18% 
-Including HPV testing: 40% 
 
Cost: 
-Pap smear: USD$ 6.43 
-Including HPV testing: 
UDS$13.12 
 
Granados-
Garcia V. 
et al, 
2014 
2.7 million Pap 
tests 
performed in 
a population 
of 9.16 million 
women 
between the 
ages of 25 and 
64 in 2010 
A cost analysis 
of the Mexican 
Institute of 
Social Security  
national 
Cervical Cancer 
Screening 
Program 
Costs were calculated 
taking into account: 
screening cost, cost for 
test confirmation, and 
treatment. Estimates of 
outcomes and costs 
were obtained using 
previously published 
information 
Mexican 
Institute of 
Social 
Security 
(the main 
Public 
Hospital in 
Mexico) 
Regional 
coverage 
rates 
reported by 
the Mexican 
Institute of 
Social 
Security 
-Cost to perform 2.7 million Pap 
smears: 38 million dollars,  
- Pap smears represent 26.1% of 
the total program cost  
-False negatives account for 43% 
of the total program costs 
Lazcano-
Ponce et 
al, 2008 
 Using data from 
national 
indicators, the 
authors 
determined the 
correlation 
between 
cervical cancer 
mortality rates 
and Pap 
coverage, 
birthrate, and 
The authors 
determined relative 
risk of dying of cervical 
cancer according to 
place of residence 
(rural/urban, region) 
using a Poisson model, 
and estimated Pap 
smear coverage using 
national survey data 
Mexican 
Institute of 
Social 
Security 
(the main 
Public 
Hospital in 
Mexico) 
Pap smear 
coverage and 
precision as 
well as 
cervical 
cancer 
mortality 
*An increase in Pap coverage (β = 
−0.069) and a decrease in 
birthrate (β = 0.054) correlate 
with decreasing cervical cancer 
mortality in Mexico.  
*Self-reported Pap smear rates in 
vary from 27.4% to 48.1%. 
*Women who live in the south 
(relative risk, 1.47) have a greater 
relative risk of dying of cervical 
cancer than those who live in the 
north 
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Study Population  
Method/ 
Study Design 
Comparison  Setting 
Outcome 
Measures 
Results 
gross national 
product, using a 
linear 
regression 
model 
*High incidence of false 
negatives in cervical cytology 
laboratories in Mexico, from 
3.33% to 53.13% 
Muñoz, 
N.et al, 
2011 
20 256 
Mexican 
women aged 
between 25 
and 65 years 
of low 
socioeconomic 
status to HPV 
testing 
(n=9202) or to 
Pap smear 
(n=11 054). 
Randomized 
controlled trial  
Pap smear versus HPV 
testing 
Mexican 
Institute of 
Social 
Security 
(the main 
Public 
Hospital in 
Mexico) 
Rates of 
cervical 
abnormalities 
and cervical 
cancer 
Rate of cervical abnormalities 
detection: 
-Pap smear: 0.38% 
-HPV testing: 10% (HPV testing 
detected 4.2 times more invasive 
cervical cancer than Pap smear) 
Murillo, 
et al, 
2016 
 Population-
based data 
from cancer 
registries in 13 
countries and 
mortality data 
from 18 
countries in 
CSA were 
analyzed. 
 Countries 
in Central 
and South 
America 
(CSA) 
Cervical 
cancer 
incidence and 
mortality 
*Cervical cancer incidence and 
mortality have decreased in 
some CSA countries 
*Annual percentage change from 
−4.2 to −6.7 for incidence and 
−0.2 to −8.3 for mortality 
*Seven countries have age-
standardized mortality rates over 
10 per 100,000 women (those 
with the lowest income levels) 
Yunes-
Diaz, E. 
eta al, 
2015 
From October 
2008–March 
2009 
An assessment 
was performed 
of the quality of 
Pap readings in 
19 cytology 
laboratories 
(CLs) in Mexico 
from the 
Cervical Cancer 
Screening 
Program 
Nine CLs were affiliated 
with the Health 
Ministry (SSA), and ten 
were affiliated with the 
Mexican Social Security 
Institute (IMSS); their 
samples were later 
interpreted by a team 
of three expert 
cytopathologists 
Mexico Quality of 
Pap smear 
reading  
*30% of the SSA reading centers 
had a sensitivity of at least 80% 
*Not one of the 10 IMSS 
laboratories evaluated reached 
this figure 
*Some reading centers had a 
sensitivity <65%, meaning that 
nearly half of the cervical cancer 
cases were not identified 
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Appendix C. Capacity to screen for Cervical Cancer in Latin America (Luciani, 2013) 
 
Parameter South America
Mexico and Central 
America
“Latin” Caribbean “English” Caribbean
Pap smear All countries All countries All countries
All countries and 
territories
HPV DNA test
Argentina, Brazil, Chile, 
Colombia, Ecuador, 
Paraguay, Uruguay and 
Venezuela
Mexico None Bahamas
